Table 1.
Psoriatic arthritis treatment toolbox
| Therapy Class | Therapies |
|---|---|
| Oral therapiesa | MTX, sulfasalazine, cyclosporine, leflunomide, apremilast |
| TNF inhibitors | Etanercept, infliximab, adalimumab, golimumab, certolizumab pegol |
| IL-12/23 inhibitor | Ustekinumab |
| IL-17A inhibitors | Secukinumab, ixekizumab |
| CTLA-4 Ig | Abatacept |
| JAK/STAT inhibitor | Tofacitinib |
| Symptomatic therapies | nonsteroidal anti-inflammatory drugs, glucocorticoids, local glucocorticoid injections |
| Psoriasis therapies | Topical therapies Phototherapy Other oral therapies: retinoids IL-17R blocker: brodalumab IL-23 inhibitors: guselkumab, tildrakizumab, rizankizumabb |
| Non-pharmacological therapies | Physical therapy, occupational therapy, smoking cessation, weight loss, massage therapy, exercise |
a
Oral therapies are termed ‘oral small molecules’ in the ACR/NPF treatment guidelines and are split into ‘cs-DMARDs’ (top row) in the GRAPPA and EULAR recommendations and apremilast in its own group (phosphodiesterase-4 inhibitor).
b
Rizankizumab is approved in Japan and recently approved in the USA (April 2019) and thus was included in the 2019 American Academy of Dermatology/National Psoriasis Foundation (AAD/NPF) treatment guidelines for psoriasis. JAK: Janus kinase; STAT: signal transducer and activator of transcription.